GIP-36 = GIP-34*
*GIP-36 is a more efficient form of the GIP-34 peptide:
(Two amino acids were added to enhance the uptake and passage of the peptide through the cell surface membrane.)
GIP-36 is the culmination of Dr. Jerry Mizejewski’s lifelong passion. Dr. M. has spent forty years researching and studying the workings of this powerful chain of amino acids. His dream from the beginning was to educate the public on his findings, and ultimately make this peptide available to all. Finally, his dream has come true! For the first time ever GIP-36 is available to you in capsule form. Research has shown that GIP-36 can help regulate bodily cell growths. And that’s just part of the story. “The research on its many benefits speaks for itself,” according to Dr. M. The man we call “Prince of Peptides” can’t wait for you to find out about GIP-36.
In the words of Dr. M
Research Reports
1.) Mizejewski GJ (2013) Review of the adenocarcinoma cell surface receptor for human alpha-fetoprotein; proposed identification of a widespread mucin as the tumor cell receptor. Tumour Biol. 34(3):1317-1336. Review of the adenocarcinoma cell surface receptor for human alpha-fetoprotein; proposed identification of a widespread mucin as the tumor cell receptor – PubMed
2.) Mizejewski GJ (2014) The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: Is the same receptor present on circulating monocytes and macrophages? A commentary. [Review] Tumour Bio. 35(8):7397-7402. The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: is the same receptor present on circulating monocytes and macrophages? A commentary – PubMed
3.) Mizejewski GJ (2015) The alpha-fetoprotein third domain receptor binding fragment: in search of scavenger and associated receptor targets. J. Drug Target. 23(6):538-551. The alpha-fetoprotein third domain receptor binding fragment: in search of scavenger and associated receptor targets – PubMed
4.) Mizejewski GJ (2015) Nonsecreted cytoplasmic alpha-fetoprotein: a newly discovered role in intracellular signaling and regulation. An update and commentary. Tumour Biol. Pp.1-8 published online 12 July 2015. Nonsecreted cytoplasmic alpha-fetoprotein: a newly discovered role in intracellular signaling and regulation. An update and commentary – PubMed
5.) Mizejewski GJ (2016) The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins. Tumour Biol. 37(9):12697-711. Epub 2016/10/27.
6.) Mizejewski GJ (2016) The third domain fragments of alpha-fetoprotein (AFP): mapping AFP interactions with selective and non-selective cation channels. Curr. Topics Peptide Protein Res (in press). (PDF) The third domain fragments of alpha-fetoprotein (AFP): Mapping AFP interaction sites with selective and non-selective cation channels
7.) Mizejewski GJ, Muehlemann M, and Dauphinee M (2006) Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor growth and metastasis. Chemotherapy 52(2):83-90. Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor growth and metastasis – PubMed
8.) Mizejewski GJ and Butterstein G (2006) Survey of functional activities for alpha-fetoprotein growth inhibitory peptides: review and prospects. Curr. Protein Pept. Sci 7(1):73-100. Survey of functional activities of alpha-fetoprotein derived growth inhibitory peptides: review and prospects – PubMed
9.) Eisele LE, Mesfin FB, Bennett JA, Andersen TT, Jacobson HI, Soldwedel H, MacColl R, Mizejewski GJ (2001). Studies on a growth-inhibitory peptide derived from alpha-fetoprotein and some analogs. J. Peptide Res 57(1):29-38. Studies on a growth-inhibitory peptide derived from alpha-fetoprotein and some analogs – PubMed
10.) Mizejewski GJ (2001) Peptides as receptor ligand drugs and their relationship to G-coupled signal transduction. Expert Opin. Investig Drugs 10(6): 1063-1073. Peptides as receptor ligand drugs and their relationship to G-coupled signal transduction – PubMed
11.) Eisele LE, Mesfin FB, Bennett JA, Andersen TT, Jacobson HI, Vakharia DD, MacColl R, and Mizejewski GJ (2001) Studies on analogs of a peptide derived from alpha-fetoprotein having antigrowth properties. J. pept. Res. 57(6): 539-546. Studies on analogs of a peptide derived from alpha-fetoprotein having antigrowth properties – PubMed
12.) MacColl R, Eisele LE, Stack RF, Hauer C, Vakharia DD, Benno A, Kelly WC, and Mizejewski GJ (2001). Interrelationships among biological activity, disulfide bonds, secondary structure, and metal ion binding for a chemically synthesized 34-amino-acid peptide derived from alpha-fetoprotein. Biochim, Biophys, Acta 1528(2-3): 127-134 Interrelationships among biological activity, disulfide bonds, secondary structure, and metal ion binding for a chemically synthesized 34-amino-acid peptide derived from alpha-fetoprotein – PubMed
13.) Butterstein G, Morrison J, and Mizejewski GJ (2003) Effect of Alpha-fetoprotein and derived peptides on insulin- and estrogen-induced fetotoxicity. Fetal Diagn, Ther 18(5):360-369. Effect of alpha-fetoprotein and derived peptides on insulin- and estrogen-induced fetotoxicity – PubMed
14.) Butterstein G, MacColl R, Mizejewski GJ, Eisele LE, and Meservey M (2003) Biophysical studies and anti-growth activities of a peptide, a certain analog and a fragment peptide derived from a alpha-fetoprotein. J. peptide res 61(4):213-218. Biophysical studies and anti-growth activities of a peptide, a certain analog and a fragment peptide derived from alpha-fetoprotein – PubMed
15.) Mizejewski GJ, Smith G, and Butterstein G (2004). Review and proposed action of alpha-fetoprotein growth inhibitory peptides as estrogen and cytoskeleton-associated factors. Cell Biol. Int. 28(12):913-933. Review and proposed action of alpha-fetoprotein growth inhibitory peptides as estrogen and cytoskeleton-associated factors – PubMed
16.) Allen SH, Bennett Ja, Mizejewski GJ, Andersen TT, Ferraris, and Jacobson HI (1993) Purification of alpha-fetoprotein from human cord serum with demonstration of its antiestrogenic activity. Biochim. Biophys. Acta 1202(1): 135-142. Purification of alpha-fetoprotein from human cord serum with demonstration of its antiestrogenic activity – PubMed
17.) Mizejewski GJ (1995). Alpha-fetoprotein binding proteins: implication for transmembrane passage and subcellular localization. Life Sci. 56(1):1-9. (Invited Review) Alpha-fetoprotein binding proteins: implications for transmembrane passage and subcellular localization – PubMed
18.) Mizejewski GJ, Dias JA, Hauer CR, Henrikson KP, Gierthy J (1996). Alpha-fetoprotein derived synthetic peptides: assay of an estrogen-modifying regulatory segment. Mol. Cell Endocrinol 118(1-2):15-23. Alpha-fetoprotein derived synthetic peptides: assay of an estrogen-modifying regulatory segment – PubMed
19.) Mizejewski GJ, Vonnegut M, and Jacobson HI (1983) Estrodiol-activated alpha-fetoprotein suppresses the uterotropic response to estrogens. Proc. Natl, Acad. Sci USA 80(9):2733-2737. Estradiol-activated alpha-fetoprotein suppresses the uterotropic response to estrogens – PMC
20.) Mizejewski GJ, Vonnegut M, and Jacobson HI (1986). Studies of the intrinsic antiuterotropic activity of murine alpha-fetoprotein. Tumour Biol 7(1):19-36.
21.) Mizejewski GJ and Warner AS (1989) alpha-fetoprotein can regulate growth in the uterus of the immature and adult ovariectomized mouse. J. reprod. Fertil 85(1): 177-185. Alpha-fetoprotein can regulate growth in the uterus of the immature and adult ovariectomized mouse – PubMed
22.) Mizejewski GJ, Keenan JF, and Setty RP (1990) Separation of the estrogen-activated growth-regulatory forms of alpha-fetoprotein in mouse amniotic fluid. Biol. Reprod. 42(5-6): 887-898. (PDF) Separation of the Estrogen-Activated Growth-Regulatory Forms of Alpha-Fetoprotein in Mouse Amniotic Fluid
23) Mizejewski GJ and Keenan JF (1991). Separation and assay of the dual growth regulatory activities of murine alpha-fetoprotein. In: New York Academy of Sciences Conference entitled “Temporal Control of Drug Delivery: (JM Hrushesky, R, Langer F, Theeuwes Es). 618:623-626.
24.) Mizejewski GJ (2024) Potential use of peptides in the targeting and therapy of solid tumor using a fetal-derived peptide: A review and prospectus. Intl. J. Clin. Mal Oncol 3(2): 1-10. (PDF) Potential Use of Peptides in the Targeting and Therapy of Solid Tumors using a Fetal-derived Peptide: A Review and Prospectus
25.) Mizejewski GJ (2024). Unraveling the association of multiple sclerosis with pregnancy, cellular immunity, and alpha-fetoproteins: A historical review and immunity analysis. Clin. Revs and Case Reports, 3(4): 1-6.
26.) Mizejewski GJ (2017) Breast cancer and transient receptor potential (TRP) cation channels: Is there a role for non-selective TRP channels as therapeutic cancer targets: a commentary. Intl. Journal of Cancer Res. And Development, 2:4-6. (PDF) Breast Cancer and Transient Receptor Potential (TRP) Cation Channels: Is There a Role for Non-Selective TRP Channels as Therapeutic Cancer Targets? A commentary
27.) Mizejewski GJ (2018) Breast cancer, chemokines, and metastasis: a search for decoy ligands of the CXCR4 receptor. Journal Neoplasms, 1:1-5. Breast Cancer, Chemokines, And Metastasis: A Search for Decoy Ligands of the CXCR4 Receptor – Open Access Pub
28.) Mizejewski GJ (2018). Cancer, circulating tumor cells, and metastasis: could protein-derived peptide fragments impede brain metastases? Journal of Cancer Metastasis and Treatment, 10:205-225. (PDF) Cancer, circulating tumor cells, and metastasis: could protein-derived peptide fragments impede brain metastases?
29.) Mizejewski GJ (2018) Alpha-fetoprotein uptake and cytoplasmic trafficking in cancer and immune-associated cells: relevance to adaptive immunity. EC Clinical and Experimental Anatomy, 1.2,1-7 (PDF) Alpha-fetoprotein Uptake and Cytoplasmic Trafficking in Cancer and Immune associated Cells: Relevance to Adaptive Immunity
30.) Mizejewski GJ (2019) Breast cancer, metastasis, and the microenvironment: disabling the tumor cell-to-stroma communication network. Journal of Cancer Metastasis and Treatment. Doi: 10.20517/2394-4722.2018.70. Breast cancer, metastasis, and the microenvironment: disabling the tumor cell-to-stroma communication network
31.) Mizejewski GJ (2019) Antimicrobial peptides and cancer: potential use of antimicrobial-like peptides in chemotherapy. J. Cancer Biol. Therap, 5:233-242. (PDF) Antimicrobial Peptides and Cancer: Potential Use of Antimicrobial-Like Peptides in Chemotherapy
32.) Mizejewski GJ (2019) Cell-penetrating versus antimicrobial peptides: comparison of potential use as cancer therapeutics. Journal of Oncology Research Forecast, 2:1013-1015 (PDF) Cell-Penetrating Versus Antimicrobial Peptides: Comparison of Potential Use as Cancer Therapeutics OPEN ACCESS
33.) Mizejewski GJ (2019) breast cancer and cell cycle inhibitors (CCIs): potential therapeutic strategies for CCI cell targeting and drug delivery. Current Advances in Oncology Res & Therapy (Issue-1): 1-8.
34.) Mizejewski GJ (2020). Disintegrin-like peptides derived from naturally occurring proteins: A proposed adjunct treatment for cancer therapy. Intl. J. Res. Mol. Mech. 5(2): 2381-3318. (PDF) Disintegrin-Like Peptides Derived from Naturally-Occurring Proteins: A Proposed Adjunct Treatment for Cancer Therapy: A Commentary
35.) Mizejewski GJ (2016) Does elevated alpha-fetoprotein during pregnancy protect against breast cancer later in life? A commentary. Anat. Physiol, 6:e139-e141. (PDF) Does Elevated Alpha-fetoprotein During Pregnancy Protect Against Breast Cancer Later in Life? A Commentary
36.) Mizejewski GJ (2016) Autoimmune disorders during pregnancy: effects of biomarkers on maternal serum screening and course of disease. Curr. Women’s Health Rev. 12(2): 95-104. (PDF) Autoimmune Disorders during Pregnancy: Effects of Biomarkers on Maternal Serum Screening and Course of Disease
37.) Mizejewski GJ, Eisele L, and MacColl R (2006) Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance of physicochemical properties. Anticancer Res. 26(4B):3071-3076. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties – PubMed
38.) Mizejewski GJ (2007) The alpha-fetoprotein-derived growth inhibitory peptie 8-mer fragment: review of a novel anticancer agents. Cancer Biother. Radiopharm. 22(1): 73-98. The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: review of a novel anticancer agent – PubMed
39.) Barha JL, Illanes s, Gonzalez-Bugatto F, Adbel-Fattah SA, Mizejewski GJ, and Soothill PW (2007) Maternal serum transformed akpha-fetoprotein levels in women with intrauterine growth retardation. Fetal Diagn. Ther 22(4): 294-298. Maternal serum transformed alpha-fetoprotein levels in women with intrauterine growth retardation – PubMed
40.) Mizejewski GJ (2009). Alpha-fetoprotein (AFP)-derived peptides as epitopes of hepatoma immunotherapy: a commentary. Cancer Immunol Immunother. 58(2):159-170. Alpha-fetoprotein (AFP)-derived peptides as epitopes for hepatoma immunotherapy: a commentary – PubMed
41.) Mizejewski GJ, Miroski M, Garnuszek P, Maurin M, Cohen BD, Poisez BJ, Posypanova GA, Makarov VA, Severin ES, and Severin SE (2010) Targeted delivery of anti-cancer growth inhibitory peptides derived from human alpha-fetoprotein: review of an international multi-center collaborative study. J. drug target 18(8): 575-588. Targeted delivery of anti-cancer growth inhibitory peptides derived from human alpha-fetoprotein: review of an International Multi-Center Collaborative Study – PubMed
42.) Mizejewski GJ (2011) Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family. Tumour Biol. 32(2): 241-258. Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family – PubMed
43.) Mizejewski GJ (2011) Mechanism of cancer growth suppression of alpha-fetoprotein derived growth inhibitory peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects. Cancers 3(2):2709-2733. Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects – PubMed
44.) Caceres G, Dauphinee MJ, Eisele Le, MacColl R, Mizejewski GJ (2002). Anti-prostate cancer and anti-breast cancer activities of two peptides derived form alpha-fetoprotein. Anticancer Res. 22(5):2817-2820. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein – PubMed
45.) Mizejewski GJ, and MacColl R (2003). Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics. Mol. Cancer ther. 2(11):1243-1255. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics – PubMed
46.) Muehlemann M, Miller KD, Dauphinee M, and Mizejewski GJ (2005). Review of growth inhibitory peptides as biotherapeutic agent for tumor growth, adhesion, and metastasis. Cancer metastasis Rev. 24(3):441-467. Review of Growth Inhibitory Peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis – PubMed
47.) Vakharia D and Mizejewski GJ (2000) Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer. Breast Cancer Res. Treat 63(1):41-52. Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer – PubMed
48.) Jacobson HI. Bennett JA, and Mizejewski GJ (1990) Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. Cancer Res. 50(2):415-420. Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol – PubMed
49.) Mizejewksi GJ (2021). Could a growth inhibitory factor, present only during pregnancy, be made available to treat cancer in adults? A commentary Internaional Journal of Cancer Research and Molecular Mechanisms, 6:1-5. (PDF) Could a Growth Inhibitory Factor, Present Only during Pregnancy, be Made Available to Treat Cancer in Adults? A Commentary
50.) Mizejewski GJ (2021) Alpha-fetoprotein and derived peptides as biomarkers and biologic response modifers: summaries, updates, and prospective. Trends in Cancer Research, Vol 16:1-25. (PDF) Alpha-fetoprotein and derived peptides as biomarkers and biologic response modifiers: Summaries, updates, and prospectives
51.) Mizejewski GJ (2023) An alpha-fetoprotein peptide suppresses growth in breast cancer and other malignancies: A review and prospectus. Med. Res. Arch 11(7). An Alpha-fetoprotein derived Peptide Suppresses Growth in Breast Cancer and Other Malignancies: A Review and Prospectus | Medical Research Archives
52.) Mizejewski GJ (2023). Ion Channels, chemokines, and metastases: Relevance to potential peptide therapy: A review and commentary. Cancers 15: 1-14. The Role of Ion Channels and Chemokines in Cancer Growth and Metastasis: A Proposed Mode of Action Using Peptides in Cancer Therapy – PMC
53.) Mizejewski GJ (2024). The role of ion channels and chemokines in cancer growth and metastasis: a proposed mode of action using peptides in cancer therapy. Cancers, 16(8): 1531-1549. The Role of Ion Channels and Chemokines in Cancer Growth and Metastasis: A Proposed Mode of Action Using Peptides in Cancer Therapy – PubMed
54.) Mizejewski GJ (2024). Role of alpha-fetoprotein and derived peptides in the remission of autoimmune diseases during pregnancy: A proposed mechanism of action. Annal Med and Med Research, 7: 1081-1089. Role of Alpha-Fetoprotein and Derived Peptides in Remission of Autoimmune Diseases During Pregnancy: A Proposed Mechanism of Action
55.) Mizejewski GJ (2024). The association of pregnancy, alpha-fetoprotein, and fetal defects with breast cancer risk: A review and commentary. J. Obstet. Gynecol and Reprod Sci 8(7): 240-249. (PDF) The Association of Pregnancy, Alpha-fetoprotein, and Fetal Defects with Breast Cancer Risk: A Review and Commentary
56.) Mizejewski GJ (2024) Unveiling the relationship of calcium ions, transient receptor potential channels, and fetal peptides with calcium induced cell death: A review and commentary: Rec. treat, Cancer Res 1(1): 1-9.